Hims & Hers Health, INC Form 4 insider transactions

Delos M. Cosgrove, a Director at Hims & Hers Health, Inc., acquired 9,935 shares of Class A Common Stock on June 12, 2025, through the vesting of Restricted Stock Units, increasing his total beneficial ownership to 64,339 shares.

Hims & Hers Health, Inc.'s Chief Medical Officer and Director, Patrick Harrison Carroll, reported the acquisition of Class A Common Stock through RSU vesting and subsequent share disposal for tax obligations.

Andrea G. Perez Garcia, a Director at Hims & Hers Health, Inc., has acquired 9,935 shares of Class A Common Stock through the conversion of Restricted Stock Units.

Hims & Hers Health, Inc. Director Kare Schultz acquired 9,118 shares of Class A Common Stock on June 12, 2025, through the vesting of Restricted Stock Units.

Hims & Hers Health, Inc. Director David B. Wells increased his direct beneficial ownership by 9,935 shares of Class A Common Stock through the vesting of Restricted Stock Units.

Michael Chi, Chief Commercial Officer of Hims & Hers Health, Inc., executed a pre-arranged transaction involving the exercise of stock options and subsequent sale of Class A Common Stock, as disclosed in a recent SEC Form 4 filing.

Michael Chi, Chief Commercial Officer of Hims & Hers Health, Inc., reported the exercise of stock options and subsequent sale of shares totaling 5,100 shares, all conducted under a Rule 10b5-1 trading plan.

Hims & Hers Health, Inc.'s Chief Financial Officer, Oluyemi Okupe, executed a pre-planned transaction on May 28, 2025, involving the exercise of stock options and the subsequent sale of Class A Common Stock.

Hims & Hers Health, Inc.'s Chief Financial Officer, Oluyemi Okupe, filed an amended Form 4 to correct the number of stock options exercised under a pre-arranged 10b5-1 trading plan.

Hims & Hers Health, Inc.'s Chief Legal Officer, Soleil Boughton, sold 3,233 shares of Class A Common Stock for approximately $180,600 as part of a Rule 10b5-1 trading plan.

Irene Becklund, an officer of Hims & Hers Health, Inc., reported the sale of 5,071 shares of Class A Common Stock for approximately $271,300, executed under a pre-arranged Rule 10b5-1 trading plan.

Chief Operating Officer of Hims & Hers Health, Inc., Nader Kabbani, reports the acquisition of 216,333 Restricted Stock Units (RSUs) tied to Class A Common Stock.

Hims & Hers Health's CFO, Oluyemi Okupe, exercised stock options and sold shares of Class A Common Stock under a pre-arranged Rule 10b5-1 trading plan.

Hims & Hers Health CEO Andrew Dudum exercised stock options and sold shares of Class A Common Stock on May 16, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Mohamed Elshenawy, Chief Technology Officer of Hims & Hers Health, Inc., was granted 1,036,339 Restricted Stock Units (RSUs) on May 12, 2025, vesting over a four-year period.

Chief Operating Officer of Hims & Hers Health, Melissa Baird, exercised stock options and sold shares of Class A Common Stock on May 12, 2025, according to a Form 4 filing with the SEC.

Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc., sold 3,235 shares of Class A Common Stock on May 12, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc., sold 3,236 shares of Class A Common Stock at a price of $30.19 per share on April 28, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Hims & Hers Health CEO Andrew Dudum exercised stock options and sold shares of Class A Common Stock on April 28 and 29, 2025, according to a Form 4 filing with the SEC.

Melissa Baird, Chief Operating Officer of Hims & Hers Health, exercised stock options and sold shares of Class A Common Stock on April 21, 2025, according to a Form 4 filing with the SEC.

Irene Becklund, PAO of Hims & Hers Health, sold 2,936 shares of Class A Common Stock at $26.49 per share on April 22, 2025, under a pre-arranged 10b5-1 trading plan.

CEO Andrew Dudum exercised stock options and sold shares of Hims & Hers Health, Inc. on April 16, 2025, according to a Form 4 filing with the SEC.

Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc., reported selling shares of Class A Common Stock on March 3, 2025, and April 14, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Hims & Hers Health CFO Oluyemi Okupe exercised stock options and sold shares of Class A Common Stock on April 15, 2025, under a pre-arranged 10b5-1 trading plan.

Chief Operating Officer of Hims & Hers Health, Melissa Baird, exercised stock options and sold shares of Class A Common Stock on April 9, 2025, according to a Form 4 filing with the SEC.

Melissa Baird, Chief Operating Officer of Hims & Hers Health, Inc., reports exercising stock options and acquiring Class A Common Stock on April 4, 2025.

Irene Becklund, PAO of Hims & Hers Health, Inc., reports selling 2,203 shares of Class A Common Stock on April 3, 2025, at a price of $28.78 per share.

Hims & Hers Health CFO Oluyemi Okupe exercised stock options and sold shares of Class A Common Stock on April 2, 2025, according to a Form 4 filing with the SEC.

Melissa Baird, Chief Operating Officer of Hims & Hers Health, exercised stock options on March 31, 2025, acquiring 13,460 shares of Class A Common Stock.

Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc., sold 3,236 shares of Class A Common Stock at a price of $27.77 per share on March 31, 2025, under a pre-arranged Rule 10b5-1 trading plan.